Citing serious safety risks and possible violations of Philippine pharmaceutical laws, the Philippine College of Physicians (PCP) has warned the public against the growing promotion and use of compounded or non-FDA registered versions of semaglutide (Ozempic) and tirzepatide (Mounjaro). In a...